A SARS-CoV-2 protein, Nsp1, may play a critical role in weakening antiviral innate immune defenses, according to a study published in Science on July 17. Researchers identified how the viral protein specifically shuts down host protein production and subsequently blocks host immune functions.  

Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.  

Pfizer and BioNTech have released initial data from an ongoing phase I/II clinical trial for the COVID-19 messenger RNA-based vaccine candidate, BNT162b1.  

A SARS-CoV-2 protein, Nsp1, may play a critical role in weakening antiviral innate immune defenses, according to a study published in Science on July 17. Researchers identified how the viral protein specifically shuts down host protein production and subsequently blocks host immune functions.  

The National Lipid Association has released an official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.  

Fears of continuing waves of infection with the SARS-CoV-2 virus have helped trigger an accelerated effort among drug developers to bring a coronavirus vaccine to market. But even after a vaccine is developed and approved, there are a host of other challenges that must be solved to make sure it is administered widely enough to protect society at large.  

Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.  

Scientists have developed a biomimetic vaccine-delivery strategy based on an innate immune function of red blood cells that can deliver vaccine nanoparticles to the spleen, according to a research article published in the Proceedings of the National Academy of Sciences on July 14.  

Pfizer and BioNTech have released initial data from an ongoing phase I/II clinical trial for the COVID-19 messenger RNA-based vaccine candidate, BNT162b1.  

Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.  

Fox Chase Cancer Center researchers have developed a new machine-learning program that could make virtual screening for cancer drugs more effective. Their findings were published July 15 in the Proceedings of the National Academy of Sciences of the United States of America.